Free Trial

Ikena Oncology (IKNA) Competitors

Ikena Oncology logo
$1.40 -0.05 (-3.79%)
As of 02/21/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IKNA vs. ATYR, IMMP, OLMA, KRRO, NMRA, YMAB, KOD, TVGN, NGNE, and ACIU

Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), Tevogen Bio (TVGN), Neurogene (NGNE), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry.

Ikena Oncology vs.

Ikena Oncology (NASDAQ:IKNA) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.

Ikena Oncology has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

In the previous week, Atyr PHARMA had 13 more articles in the media than Ikena Oncology. MarketBeat recorded 14 mentions for Atyr PHARMA and 1 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 1.88 beat Atyr PHARMA's score of 0.97 indicating that Ikena Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ikena Oncology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Atyr PHARMA
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ikena Oncology's return on equity of -36.88% beat Atyr PHARMA's return on equity.

Company Net Margins Return on Equity Return on Assets
Ikena OncologyN/A -36.88% -33.08%
Atyr PHARMA N/A -79.44%-59.16%

75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 5.9% of Ikena Oncology shares are owned by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ikena Oncology presently has a consensus price target of $3.00, indicating a potential upside of 115.83%. Atyr PHARMA has a consensus price target of $18.60, indicating a potential upside of 330.56%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than Ikena Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ikena Oncology
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Atyr PHARMA
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

Atyr PHARMA has lower revenue, but higher earnings than Ikena Oncology. Atyr PHARMA is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena Oncology$9.16M7.32-$68.17M-$1.23-1.13
Atyr PHARMA$350K1,036.06-$50.39M-$0.94-4.60

Ikena Oncology received 18 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote.

CompanyUnderperformOutperform
Ikena OncologyOutperform Votes
30
58.82%
Underperform Votes
21
41.18%
Atyr PHARMAOutperform Votes
12
100.00%
Underperform Votes
No Votes

Summary

Atyr PHARMA beats Ikena Oncology on 10 of the 18 factors compared between the two stocks.

Get Ikena Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IKNA vs. The Competition

MetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$69.97M$3.11B$5.84B$9.14B
Dividend YieldN/A1.55%4.75%3.86%
P/E Ratio-1.1330.1126.7919.19
Price / Sales7.32330.65435.1470.91
Price / CashN/A168.8738.0134.83
Price / Book0.393.687.644.62
Net Income-$68.17M-$71.72M$3.19B$246.06M
7 Day Performance-6.71%-2.52%-2.12%-2.63%
1 Month Performance-5.44%-0.33%-0.45%-2.15%
1 Year Performance4.51%-12.33%16.26%12.88%

Ikena Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IKNA
Ikena Oncology
3.4705 of 5 stars
$1.39
-4.1%
$3.00
+115.8%
+4.5%$69.97M$9.16M-1.1370Positive News
ATYR
Atyr PHARMA
2.8161 of 5 stars
$3.41
-5.0%
$19.25
+464.5%
N/A$286.24M$350,000.00-3.6353Analyst Forecast
Analyst Revision
News Coverage
Gap Up
IMMP
Immutep
0.9683 of 5 stars
$1.96
+0.5%
$8.50
+333.7%
-13.9%$285.30M$5.14M0.002,021Upcoming Earnings
Positive News
OLMA
Olema Pharmaceuticals
3.2659 of 5 stars
$4.97
+2.9%
$28.75
+478.5%
-64.0%$284.78MN/A-2.2770
KRRO
Korro Bio
0.9046 of 5 stars
$30.02
+3.2%
$144.00
+379.7%
-51.4%$281.29MN/A0.0070News Coverage
Gap Up
NMRA
Neumora Therapeutics
4.0522 of 5 stars
$1.74
+3.0%
$16.50
+848.3%
-90.0%$281.11MN/A-0.93108News Coverage
YMAB
Y-mAbs Therapeutics
2.5812 of 5 stars
$6.24
+1.1%
$20.89
+234.8%
-65.3%$279.49M$84.82M-11.56150News Coverage
KOD
Kodiak Sciences
4.2363 of 5 stars
$5.26
+3.1%
$8.00
+52.1%
-14.6%$276.78MN/A-1.4490Positive News
TVGN
Tevogen Bio
3.4186 of 5 stars
$1.58
+1.3%
$4.20
+165.8%
-82.1%$276.58MN/A0.003
NGNE
Neurogene
2.2505 of 5 stars
$18.42
-1.9%
$60.83
+230.3%
-41.7%$273.63M$925,000.000.0090
ACIU
AC Immune
2.2125 of 5 stars
$2.74
+2.2%
$12.00
+338.0%
-21.0%$271.10M$16.48M-5.96140News Coverage
Positive News
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:IKNA) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners